Amgen said interim results from a Phase 3 trial showed Imdelltra reduced the risk of death and other benefits for patients with small cell lung cancer.
The biotechnology company said the trial showed the risk of death was reduced by 40% and the median overall survival was extended by more than five months, compared with standard-of-care chemotherapy in patients with small cell lung cancer who progressed on or after one line of platinum-based chemotherapy.
At the planned interim analysis, the Phase 3 DeLLphi-304 trial met its primary OS endpoint and key secondary progression-free survival endpoint, Amgen said.
Small cell lung cancer comprises about 15% of the more than 2.4 million patients diagnosed with lung cancer each year, according to Amgen.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.